Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Fagron   /   Fagron - oktober

Aandeel Fagron BRU:FAGR.BL, BE0003874915

Laatste koers (eur) Verschil Volume
18,620   +0,340   (+1,86%) Dagrange 18,360 - 18,720 51.430   Gem. (3M) 67,2K

Fagron - oktober

Volgen
412 Posts
Pagina: «« 1 ... 16 17 18 19 20 21 | Laatste | Omlaag ↓
  4. Azoia 31 oktober 2016 23:03
    FTSE slips, though posts fifth straight month of gains
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    10/31/2016 | 05:57pm CET
    A red London bus passes the Stock Exchange in London
    Britain's top share index retreated on Monday but posted a fifth straight month of gains, as advertising group WPP rose after reporting its third-quarter results.
    The blue chip FTSE 100 <.FTSE> index was down 0.6 percent at 6,954.22 points by the close, but up 0.8 percent for October.

    Shares in WPP (>> WPP PLC) rose 4 percent and posted their biggest daily gain in four months. WPP, the world's largest advertising group, reported results in line with expectations.

    "We are encouraged by the positive nature of this morning’s update and remain fundamentally positive on WPP’s ability to capitalise on a solid medium-term outlook for global advertising spend," Roddy Davidson, an analyst at Shore Capital Markets, said in a note.

    However, investors were less optimistic about some forthcoming earnings. The top fallers were Shire (>> Shire PLC), which reports results on Tuesday, and Next (>> NEXT plc), whose results are due on Wednesday, down 2.8 percent and 3.2 percent respectively.

    The FTSE 100 index posted a fifth month of gains in a row for the first time since early 2013. The index has been buoyed by a rally in banks and mining companies.

    Banks were boosted by last week's well-received earnings from Barclays (>> Barclays PLC) and Lloyds (>> Lloyds Banking Group PLC), with the FTSE 350 banking sector <.FTNMX8350> hitting its highest level for the year.

    October saw the FTSE 100 set a record high of 7,129.83 points. A weaker pound has bolstered the index, which has rallied about 10 percent since Britain voted in June to leave the European Union. The cheaper pound helps the index's international, dollar-earning firms.

    Some analysts, however, were more cautious on the outlook for British shares.

    "(The FTSE) is still continuing the positive run of gains since Brexit, so it's a Brexit bounce. But it's run into that previous record high ... and pulled back quite significantly from there," said Jasper Lawler, market analyst at CMC Markets.

    Investors, he added, were holding back before upcoming central bank interest rate decisions and the U.S. presidential election on Nov. 8.

    "I think no one's really got the confidence to buy the market up through into new record highs."

    The more domestically exposed FTSE 250 index <.FTMC> fell 0.6 percent, and was down 1.8 percent for the month of October. It has been weighed down by a spate of profit warnings and big declines from companies including Berendsen (>> Berendsen PLC), Cobham (>> Cobham plc), Senior (>> Senior plc) and Keller (>> Keller Group plc).

    (Editing by Mark Heinrich)
  5. Azoia 31 oktober 2016 23:04
    Canada drugmaker Cipher mulls sale - sources
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    10/31/2016 | 08:25pm CET
    Cipher Pharmaceuticals Inc (>> Cipher Pharmaceuticals Inc), a Canadian specialty pharmaceuticals manufacturer, has hired an investment bank to review strategic alternatives, including a potential sale, people familiar with the matter said.
    Cipher Pharmaceuticals Inc (>> Cipher Pharmaceuticals Inc), a Canadian specialty pharmaceuticals manufacturer, has hired an investment bank to review strategic alternatives, including a potential sale, people familiar with the matter said.

    The strategic review comes amid increased U.S. scrutiny of specialty drug prices, which has weighed on the valuations of many Canadian specialty pharmaceutical companies with U.S. revenues.

    There is no certainty that a sale of Cipher will occur, the people cautioned, asking not to be identified because the deliberations are confidential.

    Shares of Cipher shot up as much as 22 percent after the Reuters report. They were up 8.3 percent on Monday afternoon in Toronto.

    "The company is working with an advisor to consider various strategic alternatives potentially available to enhance shareholder value, with a focus on the U.S. business," Cipher said in a press statement following the report.

    Toronto, Ontario-based Cipher, which has a market capitalization of $89.5 million, specializes in treatments for skin disorders. Its products include Nuvail, a topical film that treats fragile nails, and Bionect, which treats skin irritations. It has about $35 million in debt, according to regulatory filings.

    Cipher shares have dropped more than 70 percent from 2015 highs amid a broader pullback in the specialty pharmaceutical sector that has also impacted shares of Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and Concordia International Corp (>> Concordia International Corp).

    Concordia explored strategic alternatives earlier this year, before opting to improve liquidity by raising debt. Valeant has said it plans to sell about $8 billion in assets to help pay down its $30 billion debt pile.

    Cipher has been in the spotlight since its largest shareholder, John Mull, in July published a letter calling for the company's board to consider trimming its size, replacing some members of the management team and reviewing its business model. He did not call on the company to sell itself.

    In August, the board reconstituted itself, with four board members stepping down and three joining. Last month, Mull, who owns nearly 40 percent of the company, was appointed chair of the board of directors and Stephen Lemieux took over from Norman Evans as chief financial officer.

    Last year, Cipher acquired dermatology company Innocutis Holdings LLC for $45 million. In May, it bought the rights to a tattoo removal cream from Dalhousie University in Nova Scotia.

    (Reporting by Carl O'Donnell in New York and John Tilak in Toronto; Editing by Meredith Mazzilli, Bernard Orr)

    By Carl O'Donnell and John Tilak
  6. Azoia 31 oktober 2016 23:05
    Valeant Pharmaceuticals Intl : Shares Down on Bloomberg Report of Criminal Probe of Accounting
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    10/31/2016 | 09:09pm CET
    Federal prosecutors are looking into possible accounting-fraud charges against Valeant Pharmaceuticals International Inc. (>> Valeant Pharmaceuticals Intl Inc), Bloomberg News reported Monday, citing people familiar with the matter.

    Charges are possible within weeks, but no charging decisions have been made, Bloomberg reported.

    Valeant told Bloomberg "we are in frequent contact and continue to cooperate" with authorities.

    Valeant shares recently traded down 8.5% to $18.62.

    Full story at www.bloomberg.com/news/articles/2016-...

    Write to nymonitoring@dowjones.com
412 Posts
Pagina: «« 1 ... 16 17 18 19 20 21 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Fagron vult buy-&-build-strategie verder in

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Fagron Nieuws

  1. Beursblik: Kepler Cheuvreux verhoogt koersdoel Fagron licht
  2. Beursblik: opnieuw indrukwekkende groei bij Fagron
  3. Beursblik: Fagron overtreft verwachtingen
  4. Beleggers kijken kat uit de boom, maar hectische beursdag met inflatie VS, Milton en Tesla-event
  5. Omzetgroei Fagron houdt aan
  6. Hogere omzet Fagron verwacht
  7. Fagron rondt aandeleninkoopprogramma af
  8. Beursblik: KBC Securities verhoogt koersdoel Fagron
  9. Dubbeltje op zijn kant voor AEX, terwijl cijferstorm aantrekt tot windkracht 10
  10. Fagron boekt meer omzet en winst